Incyte axes blood cancer collab with Syros

In­cyte de­cid­ed not to ad­vance its blood can­cer col­lab­o­ra­tion with Sy­ros Phar­ma­ceu­ti­cals in an­oth­er blow to the biotech’s part­ner­ship port­fo­lio.

In­cyte gave no­tice Aug. 9 that it would end its myelo­pro­lif­er­a­tive neo­plasms part­ner­ship with the Cam­bridge, MA-based biotech with­in 60 days. Ac­cord­ing to an SEC fil­ing on Aug. 11, Sy­ros said “In­cyte ex­er­cised its right to ter­mi­nate the agree­ment for con­ve­nience.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.